The Impact of Post-Traumatic Stress Disorder on the Burden of Migraine: Results From the National Comorbidity Survey-Replication
Background Post‐traumatic stress disorder (PTSD) has been linked with migraine in prior studies. Objective To evaluate the individual and joint burdens of migraine and PTSD in a population‐based cohort. Methods The National Comorbidity Survey‐Replication (NCS‐R) is a general population study conduct...
Saved in:
Published in | Headache Vol. 55; no. 10; pp. 1323 - 1341 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.11.2015
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Post‐traumatic stress disorder (PTSD) has been linked with migraine in prior studies.
Objective
To evaluate the individual and joint burdens of migraine and PTSD in a population‐based cohort.
Methods
The National Comorbidity Survey‐Replication (NCS‐R) is a general population study conducted in the United States from February 2001–April 2003. PTSD and migraine were assessed, and four groups defined based on their migraine and PTSD status. The four groups included those with no migraine and no PTSD (controls, n=4535), those with migraine and without PTSD (migraine alone, n=236), those with PTSD and without migraine (PTSD alone, n=244), and those with both migraine and PTSD (mig+PTSD, n=68). Logistic and Poisson regression models were used to assess the association between dichotomous/multilevel outcome variables indicating financial, health, and interpersonal burdens and each migraine/PTSD group.
Results
Compared to controls, those with Mig+PTSD were more likely to be in the low poverty index (48% vs 41%, AOR 2.16; CI: 1.10, 4.24) and were less likely to be working for pay or profit in the past week (50% vs 68%, AOR 0.42; CI: 0.24, 0.74) but not those with migraine or PTSD alone. Additionally, the number of days where work quality was cut due to physical or mental health or substance abuse in the past month was greater in all groups compared to controls: (1) migraine alone: mean 2.57 (SEM 0.32) vs mean 1.09 (SEM 0.08) days, ARR=2.39; CI: 2.19, 2.62; (2) PTSD alone: mean 2.43 (SEM 0.33) vs mean 1.09 (SEM 0.08) days, ARR=2.09; CI: 1.91, 2.29; (3) mig+PTSD: mean 8.2 (SEM 0.79) vs 1.09 (SEM 0.08) days, ARR 6.79; CI 6.16, 7.49; and was over 2.5‐fold greater in those mig+PTSD than migraine alone (mean 8.0 [SEM 0.79] vs 2.6 days [SEM 0.72], ARR 2.77; CI: 2.45, 3.14). The likelihood of having difficulty getting along or maintaining a social life was also increased in all groups relative to controls: (1) migraine alone: 21% vs 5.4%, AOR 4.20; CI: 2.62, 6.74; (2) PTSD alone: 18% vs 5.4%, AOR 3.40; CI: 2.40, 4.82; (3) Mig+PTSD: 39% vs 5.4%, AOR 9.95; CI: 5.72, 17.32, and was 2‐fold greater in those with Mig+PTSD as compared to those with migraine alone (AOR 2.32; CI: 1.15, 4.69).
Conclusions
These findings support the need for those who treat migraine patients to be aware of the comorbidity with PTSD, as these patients may be particularly prone to adverse financial, health, and interpersonal disease burdens. |
---|---|
Bibliography: | ArticleID:HEAD12698 istex:41E0E83A57140EF773250007F9BCF401A6D23D3A ark:/67375/WNG-B8G4PV0D-K Statistical Analysis: All statistical analyses were conducted by Dr. Andrea L. Metti. Dr Scher is an Associate editor for Cephalalgia and Pain Medicine. She has grant support from the CNRM and CDMRP unrelated to the current study and is a consultant/advisory board member for Allergan. Dr Peterlin serves on the editorial boards for Headache, Neurology, and BMC Neurology and has unrelated investigator‐initiated grant support from Egalet Corporation and the Landenberger Foundation. Dr. Rao, Ms. Vieiria, Dr. Merikangas, and Dr. Metti have no conflicts of interest to disclose. Conflict of Interest The National Comorbidity Survey‐Replication (NCS‐R) is supported by the United States (U.S.) National Institute of Mental Health (NIMH; U01‐MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (Grant#044780) and the John W. Alden Trust. Collaborating NCS‐R investigators include Dr. Merikangas (co‐principal investigator, NIMH). This study was also supported by funding from the National Institute of Health/National Institute of Neurological Disorders and Stroke (K23‐NS078345) to Dr. Peterlin. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies, or the U.S. government. Dr. Peterlin had full access to all of the data in the study and takes responsibility of the integrity of the data and the accuracy of the data analysis. Funding ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0017-8748 1526-4610 |
DOI: | 10.1111/head.12698 |